Abvc Biopharma (ABVC) Notes Payables (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Notes Payables came in at $88737.0 in Q1 2026, down 88.93% YoY from $801407.0 in Q1 2025, and down 88.25% on a QoQ basis from $755512.0 in Q4 2025.
Abvc Biopharma (ABVC) Notes Payables (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Notes Payables data on file, last reported at $88737.0 in Q1 2026.
- Quarterly Notes Payables fell 88.93% year-over-year to $88737.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88737.0 (down 88.93% YoY) and the FY2025 annual result came in at $755512.0, down 10.09% from the prior year.
- Notes Payables retreated to $88737.0 in Q1 2026, from $755512.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $1.9 million in Q4 2022 to a low of $88737.0 in Q1 2026.
- A 5-year average of $1.0 million and a median of $882750.0 in 2023 frame the typical range for Notes Payables.
- Annual changes were most pronounced in 2022 — Notes Payables surged 1509.75% — and 2026, when it tumbled 88.93%.
- Tracing ABVC's Notes Payables over 5 years: stood at $1.9 million in 2022, then slumped by 52.51% to $899250.0 in 2023, then slipped by 6.56% to $840252.0 in 2024, then fell by 10.09% to $755512.0 in 2025, then tumbled by 88.25% to $88737.0 in 2026.
- The last three Notes Payables figures came in at $88737.0 (Q1 2026), $755512.0 (Q4 2025), and $809103.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - |
| 10 | Abvc Biopharma | 23.97 Mn | 23.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59,462.00 |
| Mar 31, 2026 | 88,737.00 |
| Dec 31, 2025 | 755,512.00 |
| Sep 30, 2025 | 809,103.00 |
| Jun 30, 2025 | 871,951.00 |
| Mar 31, 2025 | 801,407.00 |
| Dec 31, 2024 | 840,252.00 |
| Sep 30, 2024 | 896,250.00 |
| Jun 30, 2024 | 956,880.00 |
| Mar 31, 2024 | 842,567.00 |
| Dec 31, 2023 | 899,250.00 |
| Sep 30, 2023 | 852,500.00 |
| Jun 30, 2023 | 882,750.00 |
| Mar 31, 2023 | 902,000.00 |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 1.87 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 1.61 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Jun 30, 2021 | 1.64 Mn |